Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacogenomics (London)

• Publication date

  2016-10-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/PGS-2016-0136PMID 27790923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs

  2016cited by this paper
• A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation

  2016cited by this paper
• Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles

  2016cited by this paper
• Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations

  2016cited by this paper
• Switching STudy of Kidney TRansplant PAtients with Tremor to LCP‐TacrO (STRATO): an open‐label, multicenter, prospective phase 3b study

  2015cited by this paper
• Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

  2015cited by this paper
• Genotype-guided tacrolimus dosing in African American kidney transplant recipients

  2015cited by this paper
• Long‐term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four‐yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study

  2014cited by this paper
• Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance

  2014cited by this paper
• Novel Once‐Daily Extended‐Release Tacrolimus (LCPT) Versus Twice‐Daily Tacrolimus in De Novo Kidney Transplants: One‐Year Results of Phase III, Double‐Blind, Randomized Trial

  2014cited by this paper
• In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

  2012cited by this paper
• A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.

  2012cited by this paper
• Immunosuppression, Generic Drugs and the FDA

  2012cited by this paper
• Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.

  2011cited by this paper
• Dosing equation for tacrolimus using genetic variants and clinical factors.

  2011cited by this paper
• Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

  2010cited by this paper
• Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?

  2010cited by this paper
• New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation

  2009cited by this paper
• Tacrolimus dose in black renal transplant recipients.

  2007cited by this paper
• Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.

  2007cited by this paper
• EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO

  2006cited by this paper
• Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

  2005cited by this paper
• The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation

  2004cited by this paper
• Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper

• Pre-transplant tacrolimus fluctuations predict BK virus infection risk in kidney transplants

  2025cites this paper
• Characterizing the Use of Prolonged-Release Once-Daily Tacrolimus (LCPT) across Canada.

  2025cites this paper
• Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients

  2025cites this paper
• Biomarker-Driven Pharmacokinetics and Efficacy of Polymyxin B in Critically Ill Patients with XDR-GN Pneumonia

  2025cites this paper
• Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated

  2024cites this paper
• Guiding the starting dose of the once-daily formulation of tacrolimus in “de novo” adult renal transplant patients: a population approach

  2024cites this paper
• Pharmacogenomics and beyond! Customized pharmacotherapy for solid organ transplant recipients

  2023cites this paper
• A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations

  2023cites this paper
• Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe

  2022cites this paper
• Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients

  2022cites this paper
• Post-transplant Diabetes Mellitus in Kidney Transplant Recipients in Sudan: A Comparison Between Tacrolimus and Cyclosporine-Based Immunosuppression

  2022cites this paper
• Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation

  2022cites this paper
• Drug metabolism and drug transport of the 100 most prescribed oral drugs

  2022cites this paper
• Towards next-generation personalization of tacrolimus treatment: a review on advanced diagnostic and therapeutic approaches.

  2021cites this paper
• Anti-rejection Strategies

  2021cites this paper
• Beyond Single Nucleotide Polymorphisms: CYP3A5∗3∗6∗7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients

  2020cites this paper
• Understanding and Preventing Adverse Effects of Tacrolimus Metabolization in Transplant Patients.

  2020cites this paper
• Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial

  2020influential citation
• The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients

  2020cites this paper
• Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients

  2020cites this paper
• A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients

  2019cites this paper
• Model based dosing of tacrolimus after renal transplantation

  2019cites this paper
• A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement

  2019cites this paper
• Efficacy and safety of prolonged‐release tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus – a Phase 2, open‐label, single‐arm, one‐way crossover study

  2019cites this paper
• Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation

  2019cites this paper
• Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.

  2018cites this paper
• Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure

  2018cites this paper
• Comparative pharmacokinetics of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus

  2018cites this paper
• Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.

  2018cites this paper
• Clinical aspects of tacrolimus use in paediatric renal transplant recipients

  2018cites this paper
• "What do we know about tacrolimus pharmacogenetics in transplant recipients?"

  2018cites this paper
• Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients

  2017cites this paper
• Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation

  2017cites this paper